Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: Meta-analysis
- Authors
- Kim, Sunhwa; Baek, Jihae; Min, Hyeyoung
- Issue Date
- Nov-2012
- Publisher
- PHARMACEUTICAL SOC KOREA
- Keywords
- Granulocyte colony-stimulating factor; High dose chemotherapy; Bone marrow transplantation; Stem cell transplantation; Febrile neutropenia; Meta-analysis
- Citation
- ARCHIVES OF PHARMACAL RESEARCH, v.35, no.11, pp 2013 - 2020
- Pages
- 8
- Journal Title
- ARCHIVES OF PHARMACAL RESEARCH
- Volume
- 35
- Number
- 11
- Start Page
- 2013
- End Page
- 2020
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20083
- DOI
- 10.1007/s12272-012-1119-2
- ISSN
- 0253-6269
- Abstract
- Hematopoietic growth factors are often given for prevention of febrile neutropenia (FN), infections, and other complications by hastening neutrophil recovery in the treatment of malignancies after high dose chemotherapy (HDCT). Although several meta-analyses have already demonstrated beneficial effects of prophylactic granulocyte colony-stimulating factors (G-CSF) administration, the effects of G-CSF have not been confirmed in cancer patients receiving stem cell transplantation (SCT) after HDCT. Therefore, we performed a statistical combination of controlled clinical trials to investigate the efficacy of prophylactic use of G-CSF in preventing the neutropenic complications associated with SCT following HDCT in cancer patients. We searched PubMed to identify potentially relevant references and finally selected seven randomized controlled trials that met all of the eligibility criteria. Our meta-analysis demonstrated that prophylactic G-CSF reduced the risk of documented infections and time to hematologic recovery manifested by days to absolute neutrophil count (ANC) a parts per thousand yen 0.5 x 10(9)/L, days to ANC a parts per thousand yen 1.0 x 10(9)/L, and days to platelets a parts per thousand yen 20 x 10(9)/L in SCT patients with cancer following HDCT. The G-CSF treated group also showed a decrease in the length of hospital stay. However, there was no difference between G-CSF treatment group and placebo group in regard to all-cause mortality, infection-related mortality, grade 2 similar to 4 acute graft-versus-host-disease, and episode of fever.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20083)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.